Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting

H. T. van der Galien; M. Hoogendoorn; R. E. Kibbelaar; T. van Meerten; R. S. van Rijn

doi:10.1093/annonc/mdy482

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting

H. T. van der Galien
, M. Hoogendoorn
, R. E. Kibbelaar
, T. van Meerten
, R. S. van Rijn^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

7 Citations (Scopus)

67 Downloads (Pure)

Original language	English
Pages (from-to)	151-152
Number of pages	2
Journal	Annals of Oncology
Volume	30
Issue number	1
DOIs	https://doi.org/10.1093/annonc/mdy482
Publication status	Published - Jan-2019

Keywords

Humans
Lymphoma, Large B-Cell, Diffuse
Progression-Free Survival
Randomized Controlled Trials as Topic
Rituximab

Access to Document

10.1093/annonc/mdy482

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world settingFinal publisher's version, 176 KBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{e2bc490a8a4f488b83170943ee5866d7,

title = "Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting",

keywords = "Humans, Lymphoma, Large B-Cell, Diffuse, Progression-Free Survival, Randomized Controlled Trials as Topic, Rituximab",

author = "\{van der Galien\}, \{H. T.\} and M. Hoogendoorn and Kibbelaar, \{R. E.\} and \{van Meerten\}, T. and \{van Rijn\}, \{R. S.\}",

year = "2019",

month = jan,

doi = "10.1093/annonc/mdy482",

language = "English",

volume = "30",

pages = "151--152",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "1",

}

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting. / van der Galien, H. T.; Hoogendoorn, M.; Kibbelaar, R. E. et al.
In: Annals of Oncology, Vol. 30, No. 1, 01.2019, p. 151-152.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting

AU - van der Galien, H. T.

AU - Hoogendoorn, M.

AU - Kibbelaar, R. E.

AU - van Meerten, T.

AU - van Rijn, R. S.

PY - 2019/1

Y1 - 2019/1

KW - Humans

KW - Lymphoma, Large B-Cell, Diffuse

KW - Progression-Free Survival

KW - Randomized Controlled Trials as Topic

KW - Rituximab

U2 - 10.1093/annonc/mdy482

DO - 10.1093/annonc/mdy482

M3 - Comment/Letter to the editor

C2 - 30364941

SN - 0923-7534

VL - 30

SP - 151

EP - 152

JO - Annals of Oncology

JF - Annals of Oncology

IS - 1

ER -